MERCK @ ASCO 2017

Merck will present data for KEYTRUDA® Across 16 Types of Cancer at the 2017 ASCO Annual Meeting

Researchers will present data from **more than 50 abstracts investigating the use of KEYTRUDA as monotherapy and in novel combinations across 16 cancers, including NSCLC, melanoma, urothelial carcinoma, microsatellite instability-high (MSI-H) cancers, gastric cancer and breast cancer.** Additional longer-term PFS and OS data for KEYTRUDA in mono and as a combination therapy in first-line NSCLC from KEYNOTE-024 and KEYNOTE-021G will be presented. As noted in the abstracts, in KEYNOTE-024 significant improvement in OS was maintained with KEYTRUDA compared to chemo with a longer follow-up of approx. 6 months; and in KEYNOTE-021G with more than 5 months of additional follow-up, a trend for improved OS with KEYTRUDA + pemetrexed and carboplatin was observed when compared to pem/carbo alone, despite high rates of patient cross-over. Additional data on these findings will be presented at the meeting.

In monotherapy, data for KEYTRUDA will be presented in NSCLC, melanoma, urothelial carcinoma, gastric cancer and triple-negative breast cancer (TNBC), among others. In the combination setting, data for KEYTRUDA in NSCLC, TNBC and endometrial cancer, among others, will be presented. Additionally, studies providing insight into the role of biomarkers – such as PD-L1 and microsatellite-instability – across a variety of tumors and treatment settings will be presented. A select listing of the more than 50 Merck-sponsored and collaboration abstracts featuring KEYTRUDA is provided below. Data from studies of other oncology medicines in Merck's portfolio and pipeline will also be presented at the meeting.

Key Trial Readouts

Bladder cancer	• OS results from Phase 3 trial of KEYTRUDA compared to chemotherapy for patients with locally advanced or metastatic advanced urothelial carcinoma in the second-line setting: KEYNOTE-045 (Abstract #4501) • Biomarker analysis from the P2 trial of pts with advanced urothelial carcinoma in the 1L setting who are not eligible for cis-based chemo: KEYNOTE-052 (Abstract #4502) • New data from the phase 1/2 of KEYTRUDA and Incyte's investigational oral selective IDO1 enzyme inhibitor, epacadostat, in pts with advanced urothelial carcinoma: ECHO-202/KEYNOTE-037 (Abstract #4503).
Advanced breast cancer and other women cancers	• Phase 2 study of Pembro mono for previously treated mTNBC : KEYNOTE-086 cohort A (Abstract# 1008) • Phase 2 study of Pembro as first-line therapy for PD-L1–positive mTNBC: Preliminary data from KEYNOTE-086 cohort B. (Abstract# 1088) • Pembro plus standard neoadjuvant therapy for high-risk breast cancer: Results from I-SPY 2 (Abstract# 506) • Pembro + chemo as neoadjuvant treatment for TNBC: Prelim results from KEYNOTE-173 (Abstract #556)
Advanced GI cancers	• Efficacy and safety of Pembro monotherapy in patients with previously treated advanced gastric cancer: KEYNOTE-059 cohort 1: (Abstract 4003) • Safety and efficacy of Pembro plus 5-FU and cisplatin for 1L treatment of advanced gastric cancer: KEYNOTE-059 cohort 2 (Abstract 4012) • Phase I study of ramucirumab + Pembro in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (Abstract 4046)
Advanced Head and Neck cancer	• Genomic determinants of response to Pembro in HNSCCs (Abstract #6009) • Epacadostat plus Pembro in patients with SCCHN: Preliminary phase I/II results from ECHO-202/KEYNOTE-037 (Abstract #6010)
Advanced Lung cancer	• Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. (Abstract #9000) • 1L carboplatin and pemetrexed with or without Pembro for advanced nonsq. NSCLC: Updated results of KEYNOTE-021 cohort (Abstract #9094) • Prelim results from Phase I/ II study evaluating efficacy and safety of epacadostat plus Pembro for the treatment of pts with NSCLC: ECHO-202/KEYNOTE-037. (Abstract #9014)
Advanced Melanoma	• Long-term outcomes in patients (pts) with Ipi-naive advanced melanoma in the phase 3 study who completed Pembro treatment: KEYNOTE-006 (Abstract #9504) • Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with Pembro in anti-PD1 naïve & experienced metastatic melanoma patients (Abstract #9550) • KEYNOTE-029: Efficacy and safety of Pembro (Pembro) plus ipilimumab (ipi) for advanced melanoma (Abstract #9545) • Melanoma/Skin Cancers, ENCORE 601: A phase II study of entinostat in combination with Pembro in patients with melanoma (Abstract #9529)
Advanced Microsatellite-Instability High Cancers	• Pembro therapy for microsatellite instability high (MSI-H) colorectal cancer and non-CRC (Abstract #3071)
Advanced Renal Cell Carcinoma (RCC)	• Epacadostat plus Pembro in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037 (Abstract #4515) • Phase I/II study to assess the safety and efficacy of pazopanib and Pembro in patients with advanced renal cell carcinoma (Abstract #4506)

CORPORATE COMMUNICATIONS

"Our data at ASCO bring to life the potential of KEYTRUDA across many different cancer types as both monotherapy and in combination, and underscore the remarkable progress that is being made in the fight against cancer," said Dr. Roy Baynes, senior vice president and head of global clinical development, Chief Medical Officer, Merck Research Laboratories. "In particular, we continue to show improved survival outcomes in the first-line treatment of both melanoma and non-small cell lung cancer, and we highlight clinical collaboration data that explore the potential of novel immunotherapy combinations as a treatment for patients with cancer."